As recurrence of some gliomas, including those that are MGMT methylated57 and/or IDH-mutant127, can be delayed for many months to years, senolytics could be used during this period of latency to serve a second “punch” against therapy-induced senescent cells. Here, IDH1 is linked to central nervous system cancer.